T. Crosby
86 works · 2,198 citations · h-index 22
Top works
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
- Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
- Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
- ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
- Definitive chemoradiation in patients with inoperable oesophageal carcinoma
- Small cell oesophageal carcinoma: an institutional experience and review of the literature
- Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy
- Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1
- Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
- The Significance of Cardiac Doses Received During Chemoradiation of Oesophageal and Gastro–oesophageal Junctional Cancers
- Generation of in Vitro Autologous Human Cytotoxic T-Cell Response to E7 and HER-2/Neu Oncogene Products Using Ex-Vivo Peptide Loaded Dendritic Cells
- Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer
- Current Drug Treatment Guidelines for Epithelial Ovarian Cancer
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
- Radiobiological Determination of Dose Escalation and Normal Tissue Toxicity in Definitive Chemoradiation Therapy for Esophageal Cancer
- Oesophageal Chemoradiotherapy in the UK—Current Practice and Future Directions
- REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
- Stage for Stage Comparison of Recurrence Patterns after Definitive Chemoradiotherapy or Surgery for Oesophageal Carcinoma
- Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy
- An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning